首页 | 本学科首页   官方微博 | 高级检索  
检索        

前列腺癌bcl-2及p53蛋白表达水平的研究
引用本文:徐妙生,刘朝霞,曹世俭.前列腺癌bcl-2及p53蛋白表达水平的研究[J].首都医学院学报,2002,23(3):247-249.
作者姓名:徐妙生  刘朝霞  曹世俭
作者单位:首都医科大学附属北京天坛医院病理科 (徐妙生,刘朝霞),首都医科大学附属北京天坛医院病理科(曹世俭)
摘    要:为了研究前列腺癌bcl 2及 p5 3蛋白的表达水平及其与前列腺癌发生发展的关系 ,应用LSAB法检测了 2 8例前列腺癌患者的bcl 2及 p5 3蛋白的表达水平。结果显示 ,bcl 2及p5 3蛋白表达的阳性率分别为 4 2 .9%、2 8.6 % ,均高于良性前列腺增生的阳性率 ,但无统计学差异 (P >0 .0 5 )。在前列腺癌中 ,低分化组bcl 2的表达水平明显高于高及中分化组 (P <0 .0 5 ) ,临床分期D期明显高于B及C期 (P <0 .0 5 ) ;p5 3的表达水平在上述各组及各期之间均无统计学差异 (P >0 .0 5 )。提示前列腺癌bcl 2蛋白的表达异常增高 ,可能与前列腺癌的发生发展有关 ,检测bcl 2蛋白的表达水平可以作为前列腺癌诊断及预后判断的一项参考指标

关 键 词:前列腺癌  p53蛋白  bcl-2蛋白  免疫组织化学
收稿时间:2001-01-20
修稿时间:2001年1月20日

Expression of bcl-2 and p53 Proteins in Prostatic Carcinoma
Xu Miaosheng,Liu Zhaoxia,Cao Shijian.Expression of bcl-2 and p53 Proteins in Prostatic Carcinoma[J].Journal of Capital University of Medical Sciences,2002,23(3):247-249.
Authors:Xu Miaosheng  Liu Zhaoxia  Cao Shijian
Institution:Xu Miaosheng,Liu Zhaoxia,Cao Shijian Department of Pathology,Beijing Tiantan Hospital,Affiliate of Capital University of Medical Sciences
Abstract:Expression of bcl-2 and P53 proteins in twenty-eight cases of prostatic carcinoma and ten cases of benign hyperplasia of prostate was detected by immunohistochemical LSAB assay to study the relationship between these gene products and the pathogenesis of prostatic carcinoma. It was found that bcl-2 and p53 positive rates in prostatic carcinoma were 42.9% and 28.6% respectively, both of which were not significantly higher than those in benign hyperplasia of prostate statically, but a tendancy of their increasing expression in prostatic carcinoma could be seen. The expression of bcl-2 in the group of poor differentiation was significantly higher than that in the well-differentiated group (P<0.05). When compared in terms of clinical stages, the bcl-2 expression at stage D was significantly higher than that at stage B or C (P<0.05). There existed a tendency of increase in p53 expression in prostatic carcinoma, but it was not significantly higher than that in benign hyperplasia of prostate statistically. When the poorly differentiated group and well-differentiated group were compared, there was no statistically significant difference, and the comparison based on different clinical stages didn't show significant difference in p53 expression between stage and Stage B or C. It is suggested that bcl-2 protein expression increases in prostatic carcinoma and is, to some extent, involved in the pathogenesis of the disease. It may be concluded that bcl-2 protein assay can be used as an index of diagnosis and prognosis of the disease. The relationship between p53 expression and prostatic carcinoma remains to be learned.
Keywords:prostatic carcinoma  bcl-2 protein  p53 protein  immunohistochemistry
本文献已被 CNKI 等数据库收录!
点击此处可从《首都医学院学报》浏览原始摘要信息
点击此处可从《首都医学院学报》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号